Patents by Inventor Dipanjan Pan

Dipanjan Pan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Blood substitute composition and method of use
    Patent number: 9486508
    Abstract: The present disclosure provides oxygen-carrying nanoparticles, methods of making the nanoparticles, and methods of using the nanoparticles to carry oxygen in blood.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: November 8, 2016
    Assignee: WASHINGTON UNIVERSITY
    Inventors: Gregory M. Lanza, Dipanjan Pan, Allan Doctor, Philip C. Spinella
  • Ligand directed toroidal nanoparticles for therapy and diagnostic imaging
    Patent number: 9468607
    Abstract: The present invention provides nanoparticles, methods of making the nanoparticles, and methods of using the nanoparticles to deliver therapeutic agents and/or imaging agents.
    Type: Grant
    Filed: October 9, 2008
    Date of Patent: October 18, 2016
    Assignee: WASHINGTON UNIVERSITY
    Inventors: Gregory M. Lanza, Samuel A. Wickline, Dipanjan Pan
  • PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF
    Publication number: 20160279060
    Abstract: The present invention encompasses prodrug compositions, nanoparticles comprising one or more prodrugs, and methods of use thereof.
    Type: Application
    Filed: June 10, 2016
    Publication date: September 29, 2016
    Inventors: Gregory M. Lanza, Dipanjan Pan
  • Particles for imaging
    Patent number: 9446150
    Abstract: The invention encompasses particles comprising metal atoms, methods of making the particles, and methods for using the particles. In particular, the particles may be used to image biological tissues or to deliver a bioactive agent.
    Type: Grant
    Filed: October 9, 2008
    Date of Patent: September 20, 2016
    Assignee: WASHINGTON UNIVERSITY
    Inventors: Gregory M. Lanza, Samuel A. Wickline, Dipanjan Pan, Angana Senpan
  • BLOOD SUBSTITUTE COMPOSITION AND METHOD OF USE
    Publication number: 20160051635
    Abstract: The present disclosure provides oxygen-carrying nanoparticles, methods of making the nanoparticles, and methods of using the nanoparticles to carry oxygen in blood.
    Type: Application
    Filed: November 2, 2015
    Publication date: February 25, 2016
    Inventors: Gregory M. Lanza, Dipanjan Pan, Allan Doctor, Philip C. Spinella
  • Cell permeable nanoconjugates of shell-crosslinked knedel (SCK) and peptide nucleic acids (“PNAs”) with uniquely expressed or over-expressed mRNA targeting sequences for early diagnosis and therapy of cancer
    Patent number: 9095601
    Abstract: A functional biologically active particle conjugate useful for diagnosis and treating cancer as a bioportal comprises a nanoscale particle having associated therewith an intracellular targeting ligand comprising a PNA, or another nuclease resistant oligonucleotide analog such as MOE-mRNA (2?-methoxyethyl mRNA) or LNA (locked nucleic acid), having a sequence that binds selectively to an uniquely expressed or overexpressed mRNA specific to the cancer or disease state in a living mammal. In one aspect the uniquely overexpressed target specific to the cancer or disease state is the unr mRNA which can be targeted by the antisense sequence PNA50.
    Type: Grant
    Filed: December 5, 2012
    Date of Patent: August 4, 2015
    Assignee: WASHINGTON UNIVERSITY IN ST. LOUIS
    Inventors: Matthew L. Becker, Huafeng Fang, Xiaoxu Li, Dipanjan Pan, Raffaella Rossin, Xiankai Sun, John Stephen Taylor, Jeffrey L. Turner, Michael John Welch, Karen L. Wooley
  • CELL PERMEABLE NANOCONJUGATES OF SHELL-CROSSLINKED KNEDEL (SCK) AND PEPTIDE NUCLEIC ACIDS ("PNAs") WITH UNIQUELY EXPRESSED OR OVER-EXPRESSED mRNA TARGETING SEQUENCES FOR EARLY DIAGNOSIS AND THERAPY OF CANCER
    Publication number: 20130230452
    Abstract: A functional biologically active particle conjugate useful for diagnosis and treating cancer as a bioportal comprises a nanoscale particle having associated therewith an intracellular targeting ligand comprising a PNA, or another nuclease resistant oligonucleotide analog such as MOE-mRNA (2?-methoxyethyl mRNA) or LNA (locked nucleic acid), having a sequence that binds selectively to an uniquely expressed or overexpressed mRNA specific to the cancer or disease state in a living mammal. In one aspect the uniquely overexpressed target specific to the cancer or disease state is the unr mRNA which can be targeted by the antisense sequence PNA50.
    Type: Application
    Filed: December 5, 2012
    Publication date: September 5, 2013
    Applicant: Washington University
    Inventors: Matthew L. Becker, Huafeng Fang, Xiaoxu Li, Dipanjan Pan, Raffaella Rossin, Xiankai Sun, John Stephen Taylor, Jeffrey L. Tumer, Michael John Welch, Karen L. Wooley
  • PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF
    Publication number: 20130122100
    Abstract: Nanoparticles comprising a prodrug and prodrugs linked to phospholipids, wherein the linkages facilitate release of the prodrugs from the nanoparticles to sites within a target cell or cell membrane by fusion of the particle and the cell membrane are disclosed. Also disclosed are methods for producing and using the nanoparticles and their constituents.
    Type: Application
    Filed: April 15, 2011
    Publication date: May 16, 2013
    Applicant: THE WASHINGTON UNIVERSITY
    Inventors: Gregory M. Lanza, Dipanjan Pan
  • Cell permeable nanoconjugates of shell-crosslinked knedel (SCK) and peptide nucleic acids (“PNAs”) with uniquely expressed or over-expressed mRNA targeting sequences for early diagnosis and therapy of cancer
    Patent number: 8354093
    Abstract: A functional biologically active particle conjugate useful for diagnosis and treating cancer as a bioportal comprises a nanoscale particle having associated therewith an intracellular targeting ligand comprising a PNA, or another nuclease resistant oligonucleotide analog such as MOE-mRNA (2?-methoxyethyl mRNA) or LNA (locked nucleic acid), having a sequence that binds selectively to an uniquely expressed or overexpressed mRNA specific to the cancer or disease state in a living mammal. In one aspect the uniquely overexpressed target specific to the cancer or disease state is the unr mRNA which can be targeted by the antisense sequence PNA50.
    Type: Grant
    Filed: October 14, 2005
    Date of Patent: January 15, 2013
    Assignee: Washington University
    Inventors: Matthew L. Becker, Huafeng Fang, Xiaoxu Li, Dipanjan Pan, Raffaella Rossin, Xiankai Sun, John-Stephen Taylor, Jeffrey L. Turner, Michael John Welch, Karen L. Wooley
  • LIGAND DIRECTED TOROIDAL NANOPARTICLES FOR THERAPY AND DIAGNOSTIC IMAGING
    Publication number: 20100297007
    Abstract: The present invention provides nanoparticles, methods of making the nanoparticles, and methods of using the nanoparticles to deliver therapeutic agents and/or imaging agents.
    Type: Application
    Filed: October 9, 2008
    Publication date: November 25, 2010
    Applicant: THE WASHINGTON UNIVERSITY
    Inventors: Gregory M. Lanza, Samuel A. Wickline, Dipanjan Pan
  • PARTICLES FOR IMAGING
    Publication number: 20100297019
    Abstract: The invention encompasses particles comprising metal atoms, methods of making the particles, and methods for using the particles. In particular, the particles may be used to image biological tissues or to deliver a bioactive agent.
    Type: Application
    Filed: October 9, 2008
    Publication date: November 25, 2010
    Applicant: THE WASHINGTON UNIVERSITY
    Inventors: Gregory M. Lanza, Samuel A. Wickline, Dipanjan Pan, Angana Senpan
  • Cell permeable nanoconjugates of shell-crosslinked knedel (SCK) and peptide nucleic acids ("PNAs") with uniquely expressed or over-expressed mRNA targeting sequences for early diagnosis and therapy of cancer
    Publication number: 20060159619
    Abstract: A functional biologically active particle conjugate useful for diagnosis and treating cancer as a bioportal comprises a nanoscale particle having associated therewith an intracellular targeting ligand comprising a PNA, or another nuclease resistant oligonucleotide analog such as MOE-mRNA (2?-methoxyethyl mRNA) or LNA (locked nucleic acid), having a sequence that binds selectively to an uniquely expressed or overexpressed mRNA specific to the cancer or disease state in a living mammal. In one aspect the uniquely overexpressed target specific to the cancer or disease state is the unr mRNA which can be targeted by the antisense sequence PNA50.
    Type: Application
    Filed: October 14, 2005
    Publication date: July 20, 2006
    Inventors: Matthew Becker, Huafeng Fang, Xiaoxu Li, Dipanjan Pan, Raffaella Rossin, Xiankai Sun, John-Stephen Taylor, Jeffrey Turner, Michael Welch, Karen Wooley